Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
- DOI
- 10.1038/s41591-025-03971-6
- Published
- 2025-10-06
- Container
- Nature Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-025-03971-6,
title = {Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial},
author = {Iain B. McInnes and Laura C. Coates and Philip J. Mease and Alexis Ogdie and Arthur Kavanaugh and Lihi Eder and Georg Schett and Alan Kivitz and Dennis McGonagle and Nuala Brennan and Alex Godwood and Eva Cullen and Kristian Reich and Christopher T. Ritchlin and Joseph F. Merola},
year = {2025},
journal = {Nature Medicine},
doi = {10.1038/s41591-025-03971-6},
url = {https://doi.org/10.1038/s41591-025-03971-6}
}RIS
TY - JOUR TI - Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial AU - Iain B. McInnes AU - Laura C. Coates AU - Philip J. Mease AU - Alexis Ogdie AU - Arthur Kavanaugh AU - Lihi Eder AU - Georg Schett AU - Alan Kivitz AU - Dennis McGonagle AU - Nuala Brennan AU - Alex Godwood AU - Eva Cullen AU - Kristian Reich AU - Christopher T. Ritchlin AU - Joseph F. Merola PY - 2025 JO - Nature Medicine DO - 10.1038/s41591-025-03971-6 UR - https://doi.org/10.1038/s41591-025-03971-6 ER -
APA
McInnes, I. B., Coates, L. C., Mease, P. J., Ogdie, A., Kavanaugh, A., Eder, L., Schett, G., Kivitz, A., McGonagle, D., Brennan, N., Godwood, A., Cullen, E., Reich, K., Ritchlin, C. T., & Merola, J. F. (2025). Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03971-6
Source records
- crossref · retrieved 2026-09-25T15:28:57.120Z